Researchers discover important changes in pulmonary veins caused by COVID-19

3 June 2020
A new trial has shown that COVID-19 causes important changes in the blood veins of the lungs. The deviations in the lungs show that the virus is a lot more harmful than regular influenza.

The researchers studied how the network of pulmonary vessels was affected in COVID-19 patients. They compared these findings with the changes caused by a normal flu virus (influenza).

Damage to the smallest blood vessels

In the case of COVID-19 there were very clear and unique deviations of the pulmonary blood vessels. The smalles pulmonary veins (the capillaries) were severely damaged and contained many blood clots. The virus had also affected the walls of these vessels. A normal flu virus caused a lot less deviations in the pulmonary veins.

New blood vessels

The researchers also discovered that COVID-19 also caused the growth of numerous new blood vessels (angiogenesis). This became apparebt with the help of advanced imaging techniques and molecular research. In addition, COVID-19 appeared to cause a specific infection process in the lungs, different from that of any influenza virus.

Dr. Stijn Verleden (postdoctoral researchers in the BREATHE research group): "This research shows that the damage to the pulmonary veins played an important part in the respiratory failure and the unique clinical image (ARDS or acute respiratory distress syndrome) of COVID-19. This brings important new insights for the development of innovative therapies, specifically aimed at preventing or healing these vascular deviations."

International collaboration

The research is the result of a worldwide international collaboration of research groups in Germany (Hannover, Mainz), Belgium (Leuven), Switzerland (Basel) and the USA (Cambridge, Harvard). The respiratory diseases department and the thoracic surgery department of UZ Leuven and the KU Leuven research group BREATHE (Lab for Respiratory Diseases and Thoracic Surery) were closely involved in the research. The results of the trial were recently published in the renowned journal ‘The New England Journal Of Medicine’.

Read more

Read the full article in the New England Journal of Medicine.

More about "COVID-19"

Coronavirus (COVID-19): guidelines and measures

25 March 2020
Do you have questions about your consultation, admission or visit? Read the hospital's guidelines and measures to prevent infection and the spread of coronavirus.
More info
More about "Respiratory diseases"

Artificial intelligence for the diagnosis of lung disorders

17 June 2019
ArtiQ, a KU Leuven spin-off company which helps doctors diagnose, treat and monitor respiratory disorders, has concluded its seed financing round with € 1 million. The money will be used to develop a software platform that will be able to quickly and reliably evaluate patients' lung capacity.
More info
Last edit: 5 June 2020